Asset Details
Do you wish to reserve the book?
Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role of KEAP1, SMARCA4, and PTEN mutations
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role of KEAP1, SMARCA4, and PTEN mutations
Do you wish to request the book?
Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role of KEAP1, SMARCA4, and PTEN mutations
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Genetic drivers of tumor microenvironment and immunotherapy resistance in non-small cell lung cancer: the role of KEAP1, SMARCA4, and PTEN mutations
2025
Overview
The tumor microenvironment (TME) plays a crucial role in shaping the response to immunotherapy in non-small cell lung cancer (NSCLC). While immune checkpoint inhibitors (ICIs) have revolutionized NSCLC treatment, a significant proportion of patients exhibit primary or acquired resistance. Emerging evidence highlights the role of specific genetic alterations, Kelch-like ECH-associated protein 1 (KEAP1), SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin subfamily A member 4 (SMARCA4), and phosphatase and tensin homolog (PTEN) mutations, in driving immune evasion and limiting the effectiveness of ICIs. KEAP1 mutations, through constitutive nuclear factor erythroid 2-related factor 2 activation, promote oxidative stress adaptation and metabolic reprogramming, creating an immune-excluded TME that reduces T-cell infiltration. SMARCA4 loss disrupts chromatin remodeling and epigenetic regulation, impairing antigen presentation and fostering a poorly immunogenic tumor phenotype. PTEN inactivation, by dysregulating the PI3K/AKT pathway, enhances tumor proliferation while contributing to an immunosuppressive cytokine milieu. The presence of these mutations is associated with poor outcomes, independent of tumor mutational burden or programmed death-ligand 1 expression, and their co-occurrence, particularly with KRAS and STK11, further compounds resistance. In this review, we explore the biological impact of KEAP1, SMARCA4, and PTEN mutations on the immune landscape of NSCLC, their implications for immunotherapy resistance, and potential strategies to overcome these barriers. As precision oncology advances, identifying therapeutic vulnerabilities in these genetically defined subgroups will be critical to improving patient outcomes and expanding the efficacy of immunotherapy in NSCLC.
Publisher
BMJ Publishing Group Ltd,BMJ Publishing Group LTD,BMJ Publishing Group
Subject
/ Carcinoma, Non-Small-Cell Lung - drug therapy
/ Carcinoma, Non-Small-Cell Lung - genetics
/ Carcinoma, Non-Small-Cell Lung - immunology
/ Carcinoma, Non-Small-Cell Lung - pathology
/ Drug Resistance, Neoplasm - genetics
/ genetic
/ Humans
/ Kelch-Like ECH-Associated Protein 1 - genetics
/ Kelch-Like ECH-Associated Protein 1 - metabolism
/ Kinases
/ Ligands
/ Lung Neoplasms - drug therapy
/ Mutation
/ Nuclear Proteins - metabolism
/ Proteins
/ PTEN Phosphohydrolase - genetics
/ PTEN Phosphohydrolase - metabolism
/ Review
/ Transcription Factors - genetics
/ Transcription Factors - metabolism
/ Tumor Microenvironment - genetics
/ Tumor Microenvironment - immunology
/ tumor microenvironment - TME
/ Tumors
